GNGT1

Across TCGA pan-cancer cohorts, GNGT1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GNGT1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher GNGT1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNGT1 expression acts as an unfavorable survival marker.

PRAD, SKCM, and ESCA are the cancer types where GNGT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.088	0.774	<.001	6	view →
SKCM	OS	Median	All	0.482	0.787	.028	4	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GNGT1–PRAD (DFS)

Open the PRAD breakdown →